Literature DB >> 19850902

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.

Ambuj Kumar, Alan F List, Iztok Hozo, Rami Komrokji, Benjamin Djulbegovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19850902      PMCID： PMC2817042          DOI： 10.3324/haematol.2009.017764

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Network meta-analysis for indirect treatment comparisons.

Authors:  Thomas Lumley
Journal:  Stat Med       Date:  2002-08-30       Impact factor: 2.373

2.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.

Authors:  H C Bucher; G H Guyatt; L E Griffith; S D Walter
Journal:  J Clin Epidemiol       Date:  1997-06       Impact factor: 6.437

3.  5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.

Authors:  Ronit Gurion; Liat Vidal; Anat Gafter-Gvili; Yulia Belnik; Moshe Yeshurun; Pia Raanani; Ofer Shpilberg
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

4.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

5.  Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Authors:  Michael Lübbert; Stefan Suciu; Liliana Baila; Björn Hans Rüter; Uwe Platzbecker; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Ulrich Germing; Helmut R Salih; Filip Beeldens; Petra Muus; Karl-Heinz Pflüger; Corneel Coens; Anne Hagemeijer; Hans Eckart Schaefer; Arnold Ganser; Carlo Aul; Theo de Witte; Pierre W Wijermans
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

6.  Indirect comparisons of competing interventions.

Authors:  A M Glenny; D G Altman; F Song; C Sakarovitch; J J Deeks; R D'Amico; M Bradburn; A J Eastwood
Journal:  Health Technol Assess       Date:  2005-07       Impact factor: 4.014

7.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860
  8 in total
  7 in total

1.  A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center.

Authors:  Ruohao Xu; Xiaomei Chen; Chengxin Deng; Ping Wu; Minming Li; Suxia Geng; Peilong Lai; Zesheng Lu; Jianyu Weng; Xin Du
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

2.  An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

Authors:  Jacqueline S Garcia; Nitin Jain; Lucy A Godley
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

3.  Azacitidine in the management of patients with myelodysplastic syndromes.

Authors:  Cyrus Khan; Neeta Pathe; Salman Fazal; John Lister; James M Rossetti
Journal:  Ther Adv Hematol       Date:  2012-12

Review 4.  Stopping higher-risk myelodysplastic syndrome in its tracks.

Authors:  Daniel A Pollyea; Jonathan A Gutman
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia.

Authors:  Sang Kyun Sohn; Joon Ho Moon; Yoo Jin Lee; Sung Woo Park; Ji Yoon Kim
Journal:  Blood Res       Date:  2016-03-25

Review 6.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

7.  Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.

Authors:  Xiao Jun Huang; Kaiyan Liu; David Ritchie; Borje Andersson; Jin Lu; Jian Hou; Adolfo de la Fuente Burguera; JianXiang Wang; Allen Yeoh; Chenhua Yan; Daobin Zhou; Daryl Tan; Dong Wook Kim; Depei Wu; Elizabeth Shpall; Stephen Kornblau; Sattava Neelapu; Suradej Hongeng; Jianyong Li; Jiong Hu; Lian Sheng Zhang; Michael Wang; Pankaj Malhotra; Qian Jiang; Yazhen Qin; Raymond Wong; Richard Champlin; Frederick Hagemeister; Jason Westin; Swaminathan Iyer; Vikram Mathews; Yu Wang; Yu Hu; Zhijian Xiao; Zonghong Shao; Robert Z Orlowski; Chor Sang Chim; Stephen Mulligan; Miguel Sanz; Keiya Ozawa; Simrit Parmar; Surapol Issaragrisil
Journal:  Oncotarget       Date:  2017-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.